Axena Health has commenced a study to explore the barriers women encounter when seeking first-line treatment for urinary incontinence (UI) and faecal incontinence (FI).
Related: OrganOx and eGenesis advance in porcine liver replacement trial
The study is expected to have 500 Leva Pelvic Health System users and follows a pilot survey that indicated most women struggle with pelvic floor muscle training (PFMT) independently or with a therapist.
With these study findings, clinicians, payers, and policymakers will be able to improve access to effective UI and FI treatments.
Axena Health CEO Eileen Maus said: “A growing body of published data shows that UI and FI often go untreated. When they are treated, patients often skip to advanced therapies such as medications and surgery. My hope is that our study will help us better understand the patient journey and the barriers to first-line, conservative care.”
The company’s study will shed light on the experiences of women seeking care for UI.
Throughout the study, participants can share their experiences using the prescription medical device, Leva System.
This study is critical as it could pave the way for more accessible and effective first-line treatments, ultimately improving the lives of women worldwide.
Axena Health Patient Services and Commercial Operations vice-president Annette Brewster said: “While Kegels are accessible, they don’t work for most women.
“Physical therapy can help, but it’s not widely accessible. The Leva System offers an at-home alternative so women can access effective PFMT privately, on their own schedule.
“We’re working hard to ensure that all women have access to the Leva System and hope this study will help us continue to convince payers and providers to support women’s access to effective, convenient first-line treatment.”
In the US, 62% of adult women are affected by UI, a condition that can deteriorate the quality of life and lead to significant physical, psychological, and economic challenges.
